Related Experiment Video

Updated: Mar 29, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study

Ruxandra Ulmeanu1,2, Ileana Antohe3, Ecaterina Anisie4

  • 1a Marius Nasta Institute , Bucuresti , Romania.

Expert Review of Anticancer Therapy
|December 5, 2015
PubMed

Insights

Nivolumab shows improved survival in advanced lung cancer patients compared to docetaxel. This immunotherapy offers a promising safety profile and potential as a standalone treatment.

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Lung cancer has a high mortality rate, necessitating novel therapeutic strategies.
  • Existing treatments for advanced lung cancer have limitations.
  • Programmed death-1 (PD-1) receptor blockade is an emerging immunotherapy approach.

Purpose of the Study:

  • To compare the efficacy and safety of nivolumab versus docetaxel in advanced lung cancer.
  • To evaluate nivolumab's impact on overall survival and progression-free survival.

Main Methods:

  • Phase III clinical trial design.
  • Comparison of nivolumab (monoclonal antibody targeting PD-1) with docetaxel.
  • Assessment of survival endpoints and safety profiles.

Main Results:

  • Nivolumab demonstrated superior survival outcomes compared to docetaxel.
  • Progression-free survival was improved with nivolumab treatment.
  • Nivolumab exhibited a favorable safety profile.

Conclusions:

  • Nivolumab is an effective treatment option for advanced lung cancer.
  • The study supports nivolumab's potential as a standalone therapy.
  • Further clinical data will help define nivolumab's role in treatment paradigms.
Keywords:
NivolumabPD-1lung cancermonoclonal antibody

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K